KLR Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

KLR Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$308K	Buy	+4,497	New	+$332K	0.22%	138

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KLR Investment Advisors's LGND Position: Q1 2024 in Review

KLR Investment Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q1 2024: 4,497 shares worth $308K. The stake represents 0.22% of the portfolio and ranks #138 among its holdings.

222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

KLR Investment Advisors held 4,497 shares of Ligand Pharmaceuticals worth $308K as of Q1 2024.
Ligand Pharmaceuticals was a new KLR Investment Advisors position in Q1 2024.
Ligand Pharmaceuticals made up 0.22% of KLR Investment Advisors's portfolio in Q1 2024, its #138 holding.
222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on KLR Investment Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.